Please assess the completion status of the following clinical trial:

Trial Title: To Assess the Efficacy of Granulocyte Colony Stimulating Factor Versus Standard Medical Therapy in Patients of Decompensated Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years to75 years~* Patients of decompensated cirrhosis with CTP ≥6 and ≤ 13~* Liver transplantation not feasible soon (due to financial reasons or unavailability of donors).~Exclusion Criteria:~* Hepatocellular Carcinoma~* Sepsis (Any culture positive: blood, urine, any other obvious source of infection: UTI, SBP): Patients were included after sepsis is controlled.~* Any organ failure~* Grade 3 or 4 Hepatic Encephalopathy, Active Variceal bleed, Hepatorenal Syndrome: Patients might be included after clinical improvement~* HIV seropositivity~* Pregnancy~* Refusal to participate in the study~* Previous known hypersensitivity to G-CSF

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- GCSF+SMT (Type: EXPERIMENTAL): 5-day course of GCSF (5 μg/kg/d) plus standard medical therapy for 6 months
- SMT (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).